CME/CE

00:09:30

Optimizing The Management of Patients With Heart...

CME/CE ·

2026/10/05

Faculty: Jason Feliberti, MD Although cardiopulmonary exercise testing remains the gold standard for assessing disease progression and guiding advanced heart failure management, the 6-minute walk test plays an important role in evaluating patients in this setting. This simple test provides insight into functional capacity, prognosis, and survival while also helping clinicians monitor treatment response and disease progression. However, adherence to guideline-recommended testing

en

00:16:00

Ready, Set, Act! Opportunities to Address Persistent...

CME/CE ·

2026/08/24

Faculty: Carolyn Lam, MD, PhD Faculty: Stephen J. Greene, MD Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing persistent residual risk, and using biomarkers such as NT-proBNP to guide treatment

en

00:03:45

Reading Between the Lines: What PROMs Reveal About Itch

CME/CE ·

2026/08/17

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated

en

00:04:15

Gabapentinoids: Safety Considerations and Downstream...

CME/CE ·

2026/08/17

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated

en

00:05:30

When Itching Hurts: Quality of Life Disruption in CKD-aP

CME/CE ·

2026/08/17

Faculty: Nancy Helou, PhD Faculty: Steven Fishbane, MD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated assessment tools such as

en

00:07:30

Spotlight on Assessment: Tools That Capture CKD-aP

CME/CE ·

2026/08/17

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated

en

00:05:15

CKD-aP Uncovered Prevalence & Pathophysiology

CME/CE ·

2026/08/17

Faculty: Steven Fishbane, MD Faculty: Nancy Helou, PhD Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated assessment tools such as

en

00:05:00

From Scratch to Strategy: Talking About CKD-aP in...

CME/CE ·

2026/08/17

Faculty: Federico Alberici, MD, PhD Faculty: Anastasia Liossatou, PhD, RN Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.Topics include validated

en

00:16:30

Conference Coverage at ICCBH 2026: From...

CME/CE ·

2026/08/14

Faculty: Ravi Savarirayan, MBBS, MD Faculty: Julie Hoover-Fong, MD, PhD, FACMGG In this expert discussion, Drs. Ravi Savarirayan and Julie Hoover-Fong examine how findings from the PROPEL 3 trial of oral infigratinib fit within the evolving treatment landscape for achondroplasia in children. They review the study's efficacy and safety results in the context of currently available therapies and discuss how these data may inform treatment selection, patient counseling, and shared

en

00:32:30

Menin Inhibitors in AML: Six Clinical Showdowns That...

CME/CE ·

2026/08/10

Faculty: Amer Zeidan, MBBS, MHS Faculty: Ghayas Issa, MD, MS This chapterized expert interview examines six common clinical decision points encountered when incorporating menin inhibitors into the management of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Faculty discuss evidence-informed approaches to treatment initiation, monitoring strategies, drug-drug interaction management, adverse event mitigation, patient counseling, and workflow implementation. Drawing on

en

00:10:00

Case Consult: Targeting CDH6 in Platinum-Resistant...

CME/CE ·

2026/08/07

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn

en

00:10:30

Case Consult: Treatment Strategies for HER2-Positive...

CME/CE ·

2026/08/07

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn

en

00:11:30

Case Consult: Personalizing First-Line Maintenance...

CME/CE ·

2026/08/07

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn

en

00:09:30

Case Consult: PD-L1–Guided Treatment Decisions in...

CME/CE ·

2026/08/07

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn

en

00:09:30

Case Consult: Treatment Strategies for FRα-Positive...

CME/CE ·

2026/08/07

Faculty: Kathleen N. Moore, MD Faculty: Ritu Salani, MD This online educational activity uses real-world patient cases to explore biomarker-driven treatment strategies across the advanced ovarian cancer continuum. Expert faculty review pivotal clinical evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates, while discussing how biomarker testing guides patient selection and treatment sequencing. Through interactive case discussions, participants will learn

en

00:27:16

Redefining Durability in nAMD: The Science and...

CME/CE ·

2026/07/29

Faculty: Ashkan Abbey, MD Faculty: Rishi Singh, MD, FASRS While anti-VEGF biologics have transformed outcomes in neovascular age-related macular degeneration (nAMD), real-world data continue to show that visual gains achieved in clinical trials are not consistently replicated in practice due to various reasons. As sustained-delivery tyrosine kinase inhibitors (TKIs) advance through late-stage development, retina specialists are confronted with complex mechanistic distinctions,

en

00:31:00

Translating Research Into Practice in Breast Cancer:...

CME/CE ·

2026/07/27

Faculty: Sara A. Hurvitz, MD, FACP Faculty: Tiffany Traina, MD, FASCO The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs. Tiffany Traina and Sara Hurvitz explore the supporting data for use of ADCs in the

en

00:07:00

The Power of Timing: Therapies That Change Outcomes

CME/CE ·

2026/07/20

Faculty: Scott T. Tagawa, MD, MS Faculty: Mary-Ellen Taplin, MD This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized

en

00:07:00

ADT Intensification in Biochemically Recurrent...

CME/CE ·

2026/07/20

Faculty: Scott T. Tagawa, MD, MS Faculty: Mary-Ellen Taplin, MD This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized

en

00:05:00

Cracking the Code: Risk Stratification Guidelines to...

CME/CE ·

2026/07/20

Faculty: Scott T. Tagawa, MD, MS Faculty: Mary-Ellen Taplin, MD This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized

en

All Episodes

Similar Podcasts

This Week in Virology

Vincent Racaniello

汪诘：科学有故事（主打）

科学有故事

天方烨谈

基因频道

中科院格致论道讲坛

格致论道演讲活动

DMCN Journal

John Wiley & Sons Ltd